Insider filing · GLUE
Monte Rosa Therapeutics, Inc.
GLUE · Healthcare · 15 filings in 24 months
ticker →
Versant Venture Capital VI, L.P. sold $1.5M of Monte Rosa Therapeutics (GLUE)
Executed Oct 28 2024, disclosed Oct 30 2024, 2 days later.
Value, as filed
$1.5M
157,895 sh across 3 lots
Executed
Oct 28 2024
the trade date, as filed
Disclosed
Oct 30 2024
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
VP
Versant Venture Capital VI, L.P.
10% owner
profile →
Versant Venture Capital VI, L.P. (10% owner) filed 2 Form 4 reports as a reporting entity in the past 24 months (0 purchases, 2 sales), most often in LENZ Therapeutics, Inc. (LENZ).
The name
GLUEHealthcare · Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicin…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→